Talphera (TLPH) Liabilities from Discontinued Operations (2022 - 2026)
Talphera's (TLPH) quarterly Liabilities from Discontinued Operations came in at 650000.0 in Q1 2026, little changed year-on-year from 650000.0 in Q1 2025, and little changed quarter-over-quarter from 650000.0 in Q4 2025.
Talphera (TLPH) Liabilities from Discontinued Operations (2022 - 2026) Analysis & Trends
Talphera's Liabilities from Discontinued Operations history runs 5 years deep, the most recent figure standing at 650000.0 for Q1 2026.
- On a quarterly basis, Liabilities from Discontinued Operations changed 0.0% year-over-year to 650000.0 in Q1 2026; TTM through Mar 2026 was 650000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at 650000.0, down 10.1% from the prior year.
- Liabilities from Discontinued Operations was little changed at 650000.0 in Q1 2026 per TLPH's latest filing, from 650000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 4620000.0 in Q4 2022 and bottomed at 650000.0 in Q1 2025.
- The 5-year median for Liabilities from Discontinued Operations is 723000.0 (2024), against an average of 1225615.38.
- Across the five-year window, Liabilities from Discontinued Operations plunged 84.18% in 2023 and changed 0.0% in 2026, its largest moves.
- Year by year, Liabilities from Discontinued Operations stood at 4620000.0 in 2022, then plunged by 84.18% to 731000.0 in 2023, then dropped by 1.09% to 723000.0 in 2024, then declined by 10.1% to 650000.0 in 2025, then changed by 0.0% to 650000.0 in 2026.
- Per Business Quant, the three latest TLPH Liabilities from Discontinued Operations figures stand at 650000.0 (Q1 2026), 650000.0 (Q4 2025), and 650000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 650,000.00 |
| Mar 31, 2026 | 650,000.00 |
| Dec 31, 2025 | 650,000.00 |
| Dec 31, 2025 | 650,000.00 |
| Sep 30, 2025 | 650,000.00 |
| Sep 30, 2025 | 650,000.00 |
| Jun 30, 2025 | 650,000.00 |
| Jun 30, 2025 | 650,000.00 |
| Mar 31, 2025 | 650,000.00 |
| Mar 31, 2025 | 650,000.00 |
| Dec 31, 2024 | 723,000.00 |
| Dec 31, 2024 | 723,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Mar 31, 2024 | 730,000.00 |
| Mar 31, 2024 | 730,000.00 |
| Dec 31, 2023 | 731,000.00 |
| Dec 31, 2023 | 731,000.00 |